Skip to main content
Retour
Watch Compare

Aspire Biopharma Holdings, Inc.

Qualité des données : 100%
Également cotée sous ASBPW Nasdaq
ASBP
Nasdaq Manufacturing Chemicals
1,20 €
▲ 0,01 € (0,84%)
Cap. Boursière: 6,03 M
Prix
1,20 €
Cap. Boursière
6,03 M
Fourchette du Jour
1,13 € — 1,25 €
Fourchette 52 Semaines
0,55 € — 35,00 €
Volume
76 845
Ouverture 1,17 €
Moyenne 50J / 200J
1,29 €
6,64% below
Moyenne 50J / 200J
9,02 €
86,69% below

Quick Summary

Points Clés

Negative free cash flow of -4,92 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net Margin-394725,06%
Op. Margin-312016,95%

Sécurité

Debt / Equity
N/A
Current Ratio0,17
Interest Coverage-2,27

Valorisation

PE (TTM)
-0,25
Au-dessus de la moyenne du secteur (-1,48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -0,3 -1,5
P/B — 1,6
ROE % — -53,4
Net Margin % -394725,1 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 6 202,0 Net Income (TTM) -24,48 M
ROE N/A ROA -1443,21%
Gross Margin -1,87% Operating Margin -312016,95%
Net Margin -394725,06% Free Cash Flow (TTM) -4,92 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,17
Interest Coverage -2,27 Asset Turnover 0,00
Working Capital -11,46 M Tangible Book Value -11,47 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,25 Forward P/E N/A
P/B Ratio N/A P/S Ratio 972,10
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -81,66%
Market Cap 6,03 M Enterprise Value 6,03 M
Per Share
EPS (Diluted TTM) -16,38 Revenue / Share 0,00
FCF / Share -0,98 OCF / Share -0,98
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 20,11%
SBC-Adj. FCF -19,05 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue 6 202,0 — — —
Net Income -24,48 M -12,54 M 4,46 M 3,34 M
EPS (Diluted) -16,38 — — —
Gross Profit -116,0 — — —
Operating Income -19,35 M — — —
EBITDA — — — —
R&D Expenses 923 914,0 — — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense 8,53 M 891 624,0 8 966,0 —
Income Tax 1 013,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 1,31 M 6,71 M 19,98 M 300,18 M
Total Liabilities 7,69 M 15,62 M 403 328,0 11,12 M
Shareholders' Equity -6,38 M -15,57 M -322 105,0 -9,94 M
Total Debt — — — —
Cash & Equivalents — — — —
Current Assets 1,31 M 45 842,0 81 223,0 1,10 M
Current Liabilities 7,59 M 15,62 M 403 328,0 303 323,0